TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28355511

Group type: EXPERIMENTAL
Intervention: DHA (docosahexaenoic acid) at a dose of 60 mg per kilogram of body weight per day
Number of subjects: 1273

Group type: COMPARATOR
Intervention: Control (soy emulsion without DHA)
Number of subjects: 1273

Group type: EXPERIMENTAL
Intervention: DHA
Number of subjects: 1273

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1273
Study: 29911602

Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide and oxygen
Number of subjects: 70

Group type: COMPARATOR
Intervention: 50% oxygen in air
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups (N2O and 50% O2)
Number of subjects: 70
Study: 23964933

Group type: EXPERIMENTAL
Intervention: Vedolizumab (300 mg)
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: Vedolizumab every 8 weeks
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: Vedolizumab every 4 weeks
Number of subjects: 1576

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 1576
Study: 21397251

Group type: EXPERIMENTAL
Intervention: Generating delayed keywords prior to judging comprehension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generating delayed keywords
Number of subjects: 0
Study: 18389332

Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg/day) plus Atorvastatin (20 mg/day)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Amlodipine (10 mg/day)
Number of subjects: 126
Study: 16849078

Group type: EXPERIMENTAL
Intervention: Triple-headed toothbrush (TH-TB)
Number of subjects: 94
Study: 15358643

Group type: EXPERIMENTAL
Intervention: Photopheresis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham pheresis (placebo)
Number of subjects: 40
Study: 11379837

Group type: EXPERIMENTAL
Intervention: Risperidone (mean daily dose 2.9 mg, range 1.5-4 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 38
Study: 9404739

Group type: EXPERIMENTAL
Intervention: Transbronchial biopsy (TBB) with hematoxylin-eosin staining
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Overall assessment of TBB
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Transbronchial biopsy (TBB)
Number of subjects: 105
Study: 7971429

Group type: EXPERIMENTAL
Intervention: Caregiver Quality of Life Index (CQLI)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Hospice Quality of Life Index (HQLI)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Caregiver's perception of the patient's quality of life
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: CQLI
Number of subjects: 130
Study: 3310529

Group type: EXPERIMENTAL
Intervention: 24-hour distributed message group
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Chamber REST (various groups)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Flotation REST
Number of subjects: 9
Study: 30648112

Group type: EXPERIMENTAL
Intervention: Retinopathy
Number of subjects: 6068

Group type: EXPERIMENTAL
Intervention: Neuropathy
Number of subjects: 6068
Study: 27044557

Group type: EXPERIMENTAL
Intervention: Intravenous thiamine (200 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 26679768

Group type: EXPERIMENTAL
Intervention: Practical Approach to Lung Health strategy intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training of informal health providers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 24300152

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 20439065

Group type: EXPERIMENTAL
Intervention: Calcium supplement only
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: Calcium/vitamin D supplement
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: Vitamin D supplement only
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: Antiosteoporosis medications
Number of subjects: 2069
Study: 18421460

Group type: EXPERIMENTAL
Intervention: Educational leaflet on prostate cancer screening methods
Number of subjects: 1500

Group type: COMPARATOR
Intervention: No educational leaflet (only physician information during interview)
Number of subjects: 1500
Study: 16391243

Group type: EXPERIMENTAL
Intervention: Above-the-elbow cast
Number of subjects: 102

Group type: COMPARATOR
Intervention: Below-the-elbow cast
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study: 12772751

Group type: EXPERIMENTAL
Intervention: Pirenzepine eye drops
Number of subjects: 0
Study: 10900497

Group type: EXPERIMENTAL
Intervention: 1.5 micrograms/kg clonidine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 50 micrograms/kg midazolam
Number of subjects: 150

Group type: COMPARATOR
Intervention: No premedication (control)
Number of subjects: 150
Study: 8610922

Group type: EXPERIMENTAL
Intervention: Cholesterol-reducing drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 1407926

Group type: EXPERIMENTAL
Intervention: Intravenous and oral magnesium
Number of subjects: 98

Group type: COMPARATOR
Intervention: Subcutaneous and oral terbutaline
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Oral magnesium
Number of subjects: 98

Group type: COMPARATOR
Intervention: Subcutaneous terbutaline
Number of subjects: 98
Study: 4018179

Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg/day) for 8 weeks
Number of subjects: 15
Study: 28816242

Group type: EXPERIMENTAL
Intervention: Basimglurant 0.5 mg
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Basimglurant 1.5 mg
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 27604770

Group type: EXPERIMENTAL
Intervention: DHA (400 mg/day)
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1094
Study: 24884739

Group type: EXPERIMENTAL
Intervention: E-learning course on delirium for nursing staff
Number of subjects: 3263

Group type: COMPARATOR
Intervention: Control phase (no e-learning course)
Number of subjects: 3263

Group type: EXPERIMENTAL
Intervention: Intervention phase (with e-learning course)
Number of subjects: 3263
Study: 22239205

Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Short message service
Number of subjects: 77
Study: 19926261

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 1178
Study: 18547293

Group type: EXPERIMENTAL
Intervention: 3 mg morphine in 10 ml saline
Number of subjects: 25

Group type: COMPARATOR
Intervention: 10 ml saline
Number of subjects: 25
Study: 16463864

Group type: EXPERIMENTAL
Intervention: Hypothermia (34 degrees C maintained for 72 hours)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Normothermia (control group)
Number of subjects: 72
Study: 12186794

Group type: EXPERIMENTAL
Intervention: Omapatrilat (40 mg once daily)
Number of subjects: 5770

Group type: COMPARATOR
Intervention: Enalapril (10 mg BID)
Number of subjects: 5770
Study: 9933261

Group type: EXPERIMENTAL
Intervention: Nausea/vomiting within 24 hours after onset
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure >/=180 mm Hg within 12 hours
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Hypodensity of >50% of the middle cerebral artery territory on initial CT scan
Number of subjects: 135
Study: 7748048

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Ibuprofen and Naproxen
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 162
Study: 2359741

Group type: EXPERIMENTAL
Intervention: Low-intensity intervention programs focusing on changing eating patterns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-intensity intervention programs focusing on weight loss and weight-loss management
Number of subjects: 0
Study: 565645

Group type: EXPERIMENTAL
Intervention: BCG mixed with irradiated autologous melanoma cells
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no further treatment)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 15
Study: 31152048

Group type: EXPERIMENTAL
Intervention: Early palliative care
Number of subjects: 0

Group type: COMPARATOR
Intervention: First-line chemotherapy
Number of subjects: 0
Study: 28495026

Group type: EXPERIMENTAL
Intervention: Structured postoperative physiotherapy (combined neck-specific exercises with a behavioral approach)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Structured postoperative physiotherapy (with ≥50% attendance)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard postoperative approach
Number of subjects: 202
Study: 25958108

Group type: EXPERIMENTAL
Intervention: Decisional Conflict Scale (DCS) subscale - values clarity
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Decisional Conflict Scale (DCS) subscale - support
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Decisional Conflict Scale (DCS) subscale - effective decision
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Full Decisional Conflict Scale (DCS)
Number of subjects: 332
Study: 24250318

Group type: EXPERIMENTAL
Intervention: Bupivacaine wound infiltration (40 ml, 0.25%)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Saline control (40 ml, 0.9%)
Number of subjects: 46
Study: 21336630

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) plus methylphenidate (20-30 mg/day depending on weight)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo plus methylphenidate (20-30 mg/day depending on weight)
Number of subjects: 40
Study: 19169651

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) therapy initiated within 24 hours of surgery
Number of subjects: 29

Group type: COMPARATOR
Intervention: Phenytoin (PHT) therapy continued
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 29
Study: 17584551

Group type: EXPERIMENTAL
Intervention: Registry patients (not enrolled in the trial)
Number of subjects: 3726

Group type: COMPARATOR
Intervention: Trial patients (ExTRACT-TIMI 25)
Number of subjects: 3726

Group type: EXPERIMENTAL
Intervention: Registry patients (after adjusting for TIMI Risk Index)
Number of subjects: 3726

Group type: EXPERIMENTAL
Intervention: GNI (gross national income)
Number of subjects: 3726
Study: 10964731

Group type: EXPERIMENTAL
Intervention: Radiographer
Number of subjects: 100

Group type: COMPARATOR
Intervention: Radiologist
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both operators
Number of subjects: 100
Study: 8792693

Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: lansoprazole 15 mg
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg
Number of subjects: 1284

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg vs lansoprazole 15 mg
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg vs lansoprazole 15 mg
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg vs omeprazole 20 mg
Number of subjects: 1284
Study: 1620832

Group type: EXPERIMENTAL
Intervention: Hydroxyzine (100 mg tablet)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 6735042

Group type: EXPERIMENTAL
Intervention: 40 749 RP 1 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 40 749 RP 2 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 40 749 RP 4 mg/kg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30198967

Group type: EXPERIMENTAL
Intervention: 0.5mg ranibizumab monthly for 12 months
Number of subjects: 24
Study: 29235564

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC)
Number of subjects: 126

Group type: COMPARATOR
Intervention: No induction chemotherapy (Control)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: WMD with IC
Number of subjects: 126

Group type: COMPARATOR
Intervention: Very high risk (PD, cN2/N3)
Number of subjects: 126

Group type: COMPARATOR
Intervention: High risk (PD, cN0/N1, stage cIII)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Moderate risk (PD, cN0/N1, stage cI/II or WMD without IC)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Low risk (WMD with IC)
Number of subjects: 126
Study: 27388866

Group type: EXPERIMENTAL
Intervention: Teledebriefing
Number of subjects: 246

Group type: COMPARATOR
Intervention: On-site debriefing
Number of subjects: 246
Study: 26176036

Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic biliary stenting (PTBS)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Endoscopic biliary stenting (EBS)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study: 22566115

Group type: EXPERIMENTAL
Intervention: 10-minute group (manual placental removal if not spontaneously delivered by 10 minutes)
Number of subjects: 312

Group type: COMPARATOR
Intervention: 15-minute group (manual placental removal if not spontaneously delivered by 15 minutes)
Number of subjects: 312
Study: 20653164

Group type: EXPERIMENTAL
Intervention: Retention enema of the decoction for clearing away heat, expelling dampness, promoting blood circulation and healing ulcer
Number of subjects: 100

Group type: COMPARATOR
Intervention: Retention enema of the enterosoluble tablet sulfasalazine
Number of subjects: 100
Study: 18576354

Group type: EXPERIMENTAL
Intervention: Anti-CCR2 monoclonal antibody at 0.5 mg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Anti-CCR2 monoclonal antibody at 1.5 mg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Anti-CCR2 monoclonal antibody at 4.0 mg/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 15818420

Group type: EXPERIMENTAL
Intervention: Scheme I: tetracycline 500 mg qid, furazolidone 100 mg qid, colloidal bismuth subcitrate 120 mg qid for 3 days
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Scheme II: tetracycline 500 mg qid, furazolidone 100 mg qid, colloidal bismuth subcitrate 120 mg qid for 4 days
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both schemes (I and II)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Hp eradication
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Treatment (both schemes)
Number of subjects: 66
Study: 11922194

Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 10069677

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh; 50 microg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Phenylephrine (1 microM for 5 min)
Number of subjects: 20
Study: 7549273

Group type: EXPERIMENTAL
Intervention: Lotheissen-McVay method
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Shouldice method
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Marcy method
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Postempsky-Halsted I method
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Iliopubic tract repair
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Bilateral preperitoneal prosthetic repair
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Bassini's method
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (5 men who had not undergone surgery)
Number of subjects: 58
Study: 2035858

Group type: EXPERIMENTAL
Intervention: 5 mg of preservative-free morphine in 1.0 mL of 0.9% saline added to local anesthetic solution (20 mL of 1% plain lignocaine, 20 mL of 0.5% plain bupivacaine) with intramuscular placebo injection of 1.0 mL of 0.9% saline
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1.0 mL of 0.9% saline added to local anesthetic solution with intramuscular injection of 5 mg of preservative-free morphine in 1.0 mL of 0.9% saline
Number of subjects: 50
Study: 31646981

Group type: EXPERIMENTAL
Intervention: nal-IRI (mg/m2, 46h infusion)/5-FU (2400 mg/m2, 46h infusion)/leucovorin (400 mg/m2, 0.5h infusion) d1 on 14 day-cycles
Number of subjects: 92

Group type: COMPARATOR
Intervention: cisplatin (25 mg/m2, 1h infusion)/gemcitabine (1000 mg/m2, 0.5h infusion) d1 and d8 on 21 day-cycles
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: nal-IRI/5-FU/leucovorin
Number of subjects: 92

Group type: COMPARATOR
Intervention: cisplatin/gemcitabine
Number of subjects: 92
Study: 30261853

Group type: EXPERIMENTAL
Intervention: 12-week multimodal intervention including supervised exercise training, home-based walking, supportive nurse-led counseling, and protein supplement after training.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 12-week multimodal intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard oncological treatment
Number of subjects: 100
Study: 24971674

Group type: EXPERIMENTAL
Intervention: Behavioral nutrition intervention with a one-week booster added three months post-intervention.
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (no booster added).
Number of subjects: 107
Study: 25250415

Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 100

Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 100
Study: 23063049

Group type: EXPERIMENTAL
Intervention: Internet-based computerized tracking system (CTS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low usage of the CTS
Number of subjects: 0
Study: 20663629

Group type: EXPERIMENTAL
Intervention: Verona Coding Definitions of Emotional Sequences (VR‐CoDES)
Number of subjects: 28
Study: 17926336

Group type: EXPERIMENTAL
Intervention: Rapid tryptophan depletion (RTD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22
Study: 15749211

Group type: EXPERIMENTAL
Intervention: Costochondral grafts
Number of subjects: 55
Study: 12202665

Group type: EXPERIMENTAL
Intervention: Temozolomide and radiotherapy (75 mg/m(2)/d concurrent with 40‐Gy radiotherapy for 4 weeks, followed by 200 mg/m(2)/d for 5 days every 28 days for 6 cycles)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Radiotherapy alone (40‐Gy radiotherapy for 4 weeks)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Temozolomide and radiotherapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 52
Study: 10362821

Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (t-PA)
Number of subjects: 624

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 624
Study: 8521160

Group type: EXPERIMENTAL
Intervention: Family-based behavioral treatment for children
Number of subjects: 113

Group type: COMPARATOR
Intervention: Family-based behavioral treatment for parents
Number of subjects: 113
Study: 1665181

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination tablet of lisinopril and hydrochlorothiazide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Free combination of lisinopril and hydrochlorothiazide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fixed-dose combination of lisinopril and hydrochlorothiazide
Number of subjects: 24
Study: 7212793

Group type: EXPERIMENTAL
Intervention: Gastric bypass with Roux‐en‐Y gastrojejunostomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gastric partitioning procedure
Number of subjects: 0
Study: 30737098

Group type: EXPERIMENTAL
Intervention: Right-sided tumors
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Left-sided tumors with wild-type KRAS
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Left-sided tumors with mutant KRAS
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Rectal tumors with wild-type KRAS
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Rectal tumors
Number of subjects: 899

Group type: COMPARATOR
Intervention: KRAS status (wild-type vs mutant)
Number of subjects: 899
Study: 31847328

Group type: EXPERIMENTAL
Intervention: Protein-targeting fortification (PTF) group, n = 25
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fixed-fortification (FF) group, n = 23
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (PTF and FF)
Number of subjects: 48
Study: 27545051

Group type: EXPERIMENTAL
Intervention: Transosseous repair (TO group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Transosseous-equivalent repair (TOE group)
Number of subjects: 20
Study: 26377913

Group type: EXPERIMENTAL
Intervention: Opioid rotation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Opioid combination
Number of subjects: 50
Study: 23245705

Group type: EXPERIMENTAL
Intervention: Nature-based sounds (N-BS) intervention for 90 minutes using media players and headphones.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (placebo) with no nature-based sounds intervention.
Number of subjects: 60
Study: 21391015

Group type: EXPERIMENTAL
Intervention: Parent Management Training (Oregon model)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (active treatment alternative)
Number of subjects: 112
Study: 19476015

Group type: EXPERIMENTAL
Intervention: Desloratadine 2.5 mg/pseudoephedrine 120 mg (DL/PSE) bid
Number of subjects: 598

Group type: COMPARATOR
Intervention: Desloratadine 5.0 mg qd
Number of subjects: 598

Group type: COMPARATOR
Intervention: Pseudoephedrine 120 mg bid
Number of subjects: 598
Study: 17179911

Group type: EXPERIMENTAL
Intervention: 3 ml of 1.5% epidural lidocaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 ml of normal saline
Number of subjects: 60

Group type: COMPARATOR
Intervention: No test solution (Control group)
Number of subjects: 60
Study: 14714242

Group type: EXPERIMENTAL
Intervention: Cervical carbon‐fibre intervertebral fusion cage (CIFC)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Cloward procedure (CP)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: CIFC
Number of subjects: 103

Group type: COMPARATOR
Intervention: CP
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: CIFC and CP
Number of subjects: 103